» Articles » PMID: 36545500

The Role of a Novel Generation of Emollients, 'Emollients Plus', in Atopic Dermatitis

Overview
Publisher Dove Medical Press
Specialty Dermatology
Date 2022 Dec 22
PMID 36545500
Authors
Affiliations
Soon will be listed here.
Abstract

Emollients are the mainstay maintenance treatment for atopic dermatitis (AD). A novel generation of emollients, 'emollients plus', containing active, non-medicated substances, has softened the distinction between emollients and topical drugs. A literature search for selected key words was performed using PubMed. Additional papers were identified based on author expertise. Whilst the inclusion of five components of an ideal emollient has been proposed, no such consensus exists for emollients plus and they can vary markedly in their composition and modes of action for AD treatment. This could have a profound effect on their clinical efficacy. The efficacy of emollients plus in restoring and maintaining skin barrier function has been demonstrated on multiple levels, with evidence reported for their effects on the physical and biochemical, microbial, immunological, and neurosensory barriers. When selecting an appropriate AD treatment approach, the safety profiles of the available topical therapies must be carefully considered. There are several proposed treatment approaches for AD, including preventive, proactive, intermittent, and synergistic approaches. Emollients plus may be effective not only as maintenance therapy for AD, but also when used synergistically with anti-inflammatory pharmacological therapies.

Citing Articles

Novel drug delivery systems in topical treatment of atopic dermatitis.

Dabhadkar M, Kulkarni M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40080153 DOI: 10.1007/s00210-025-04002-4.


Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions.

Zhang Y, Yuan S, Wu Y, Nie W, You T, Yang H Inflammopharmacology. 2025; .

PMID: 39954187 DOI: 10.1007/s10787-025-01659-4.


Should Emollients Be Recommended for the Prevention of Atopic Dermatitis?-New Evidence and Current State of Knowledge.

Grzesk-Kaczynska M, Petrus-Halicka J, Kaczynski S, Bartuzi Z, Ukleja-Sokolowska N J Clin Med. 2024; 13(3).

PMID: 38337555 PMC: 10856443. DOI: 10.3390/jcm13030863.


Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study.

Sowlati M, Morariu S, Orzan O, Veraldi S, Dodiuk-Gad R, Orasan R Dermatol Ther (Heidelb). 2023; 13(11):2669-2679.

PMID: 37740857 PMC: 10613178. DOI: 10.1007/s13555-023-01035-6.


Topical Application of a Formulation Containing Pea Proteins and Xyloglucan in Adult Patients with Atopic Dermatitis: A Double-blind, Parallel, Randomized, Placebo-controlled, Multicenter Study.

Sowlati M, Orzan O, Morariu S, Etropolska Z, Veraldi S, Dimitrov S J Clin Aesthet Dermatol. 2023; 16(7):35-41.

PMID: 37560506 PMC: 10409507.

References
1.
Luger T, Adaskevich U, Anfilova M, Dou X, Murashkin N, Namazova-Baranova L . Practical algorithm to inform clinical decision-making in the topical treatment of atopic dermatitis. J Dermatol. 2021; 48(8):1139-1148. DOI: 10.1111/1346-8138.15921. View

2.
Andersen R, Thyssen J, Maibach H . Qualitative vs. quantitative atopic dermatitis criteria - in historical and present perspectives. J Eur Acad Dermatol Venereol. 2015; 30(4):604-18. DOI: 10.1111/jdv.13442. View

3.
Seite S, Zelenkova H, Martin R . Clinical efficacy of emollients in atopic dermatitis patients - relationship with the skin microbiota modification. Clin Cosmet Investig Dermatol. 2017; 10:25-33. PMC: 5238811. DOI: 10.2147/CCID.S121910. View

4.
Saeedi M, Morteza-Semnani K, Ghoreishi M . The treatment of atopic dermatitis with licorice gel. J Dermatolog Treat. 2003; 14(3):153-7. DOI: 10.1080/09546630310014369. View

5.
Eberlein B, Eicke C, Reinhardt H, Ring J . Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008; 22(1):73-82. DOI: 10.1111/j.1468-3083.2007.02351.x. View